NCT05698199View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 21, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Glioblastoma

Interventions

DRUG

ITI-1001

ITI-1001 DNA vaccine represents a multi-antigen nucleic acid cancer immunotherapy encoding 3 CMV antigens. The vaccine is comprised of 2 DNA plasmids: 1 plasmid encoding IE-1 and pp65 antigens as a fusion protein with LAMP1. Another plasmid encodes gB antigen as a fusion protein with LAMP1.

Trial Locations (1)

02215

Dana-Farber Cancer Institute, Boston